Anebulo Pharmaceuticals ANEB

OTC ANEB

$0.39 +0.00 (+0.00%)

At close: Sep 8, 2026 · 4:00 PM EDT

Key Stats

Market Cap14.79 Mn

P/E-1.64

Div. Yield0.00

Add ratio to table…

About

Anebulo Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on developing treatments for cannabis induced toxicity. Its lead product candidate, selonabant, is a small molecule cannabinoid receptor type 1 (CB1) antagonist designed to rapidly reverse the effects of tetrahydrocannabinol (THC) exposure. The company is advancing both oral and intravenous formulations of selonabant to address acute cannabinoid intoxication in adults and unintentional cannabis poisoning in children. Currently there are no FDA approved therapies that specifically target cannabis toxicity, creating an unmet medical need that selonabant aims to fill. Anebulo’s efforts are driven by rising emergency department visits linked to THC edibles, which have become more prevalent as more states legalize cannabis for medical and recreational use.

Anebulo Pharmaceuticals, Inc. does not currently generate product revenue because it has no approved drugs on the market. The company’s future revenue will depend on the successful development, regulatory approval, and commercialization of selonabant, potentially through product sales, licensing agreements, or strategic collaborations with larger pharmaceutical firms. To advance its programs, Anebulo finances its operations through private placements, public equity offerings, and other financing activities. As of June 30, 2025, the company reported research and development expenses of approximately $4.3 million, reflecting its investment in preclinical studies, clinical trials, and regulatory work. Until a product reaches the market, the company relies on these funding sources to sustain its operations and continue advancing selonabant through clinical development.

Anebulo Pharmaceuticals, Inc. occupies a niche within the broader pharmaceutical industry as one of the few companies pursuing a targeted therapy for cannabis induced toxicity. While larger biotech firms and academic groups explore cannabinoid based treatments for various indications, Anebulo’s focus on reversing THC effects via CB1 antagonism differentiates it from competitors such as Aelis Farma, which is developing a pregnenolone derived agent for cannabis use disorders. The lack of any approved treatment for acute cannabinoid intoxication gives Anebulo a first in class opportunity, and its patent portfolio, which includes 3 issued U. S. patents and pending applications, provides a protective barrier against potential entrants. Anebulo’s strategy emphasizes the intravenous formulation for pediatric patients, a path it believes may accelerate regulatory approval compared with an oral adult indication. The company’s recent interactions with the FDA, including a pre IND meeting for the IV formulation in December 2024, demonstrate a collaborative approach aimed at efficiently advancing the selonabant program for pediatric indications.

The company anticipates that its primary customers will be hospital emergency departments, pediatric clinics, and toxicity centers that treat patients suffering from acute cannabis exposure. Although no specific customer names are disclosed in the filing, the intended user base includes healthcare providers caring for both adult patients with acute cannabinoid intoxication and pediatric victims of unintentional THC ingestion. These providers are concentrated in states where cannabis containing edibles are widely available, reflecting the geographic pattern of increased legalization and associated consumption trends. Anebulo intends to position selonabant as a rapid acting therapy that can reduce the time to recovery and alleviate the burden on emergency resources. By focusing on the pediatric IV formulation, the company seeks to address a vulnerable population that currently lacks any approved treatment options for severe cannabis toxicity.

Investment Thesis

▲ Bull case

Anebulo Pharmaceuticals is strategically prioritizing the development of an intravenous (IV) formulation of its lead candidate, selonabant, for pediatric patients with acute cannabis-induced toxicity, a decision that could significantly accelerate the path to regulatory approval and market entry compared to pursuing the adult oral formulation first. By focusing on the IV route for children, the company is targeting a high-urgency, underserved medical need where rapid reversal of THC exposure can lead to severe neurological symptoms requiring immediate intervention in emergency settings. This pediatric focus may qualify for regulatory incentives such as orphan drug designation, priority review, or pediatric exclusivity, which could shorten development timelines and reduce commercialization risks. The successful completion of a Phase 1 SAD study of IV selonabant in September 2025 demonstrates tangible progress in formulation development, and the prior Phase 2 proof-of-concept data showing oral selonabant effectively blocked or reversed THC-induced CNS effects without serious adverse events provides a strong mechanistic and safety foundation for the IV version. This strategic pivot reflects a nuanced understanding of regulatory pathways and unmet clinical needs, positioning the company to potentially capture value faster in a niche but critical segment of cannabis toxicity treatment.
The company’s decision to pursue voluntary delisting from Nasdaq and deregistration with the SEC, while seemingly defensive, could unlock substantial operational and financial efficiencies that directly benefit long-term value creation. By eliminating the recurring costs of SEC reporting, Sarbanes-Oxley compliance, audit fees, legal expenses, and Nasdaq listing standards, Anebulo can redirect significant capital toward its core R&D mission—particularly the advancement of the IV selonabant program. With cash and cash equivalents of $9,041,570 as of December 31, 2025, and a net loss narrowing to $1,999,397 for Q2 FY26 (down from $2,463,030 in the prior year period), the company is demonstrating improving financial discipline. The delisting process, expected to be completed by late February 2026, will reduce non-essential expenditures, allowing management to focus exclusively on clinical development and regulatory strategy without the distraction of public company obligations. This shift could extend the company’s cash runway meaningfully, especially if combined with potential non-dilutive funding from grants or partnerships, which the company has already shown success in securing (e.g., grant income of $552,576 in Q2 FY26).
The recent oversubscribed self-tender offer, in which 4,907,881 shares were tendered against an offer for only 300,000 shares at $3.50 per share, reveals strong underlying shareholder support and confidence in the company’s long-term vision, despite its clinical-stage status and lack of near-term revenue. The tender was oversubscribed by more than 16x, indicating that a significant portion of the shareholder base believes the current market price undervalues the company’s potential, particularly given the premium offered relative to recent trading levels. This level of participation suggests that institutional and retail investors alike are aligned with management’s strategic direction—focusing on pediatric IV selonabant and preparing for a potential future relisting or strategic transaction after value inflection points are achieved. The tender also reduced the shareholder base, which was a stated goal to facilitate deregistration, thereby streamlining governance and reducing administrative complexity. Far from being a sign of distress, this action reflects a proactive effort to align the shareholder structure with the company’s transition to a leaner, more focused operational model post-delisting.

Anebulo Pharmaceuticals is strategically prioritizing the development of an intravenous (IV) formulation of its lead candidate, selonabant, for pediatric patients with acute cannabis-induced toxicity, a decision that could significantly accelerate the path to regulatory approval and market entry compared to pursuing the adult oral formulation first. By focusing on the IV route for children, the company is targeting a high-urgency, underserved medical need where rapid reversal of THC exposure can lead to severe neurological symptoms requiring immediate intervention in emergency settings. This pediatric focus may qualify for regulatory incentives such as orphan drug designation, priority review, or pediatric exclusivity, which could shorten development timelines and reduce commercialization risks. The successful completion of a Phase 1 SAD study of IV selonabant in September 2025 demonstrates tangible progress in formulation development, and the prior Phase 2 proof-of-concept data showing oral selonabant effectively blocked or reversed THC-induced CNS effects without serious adverse events provides a strong mechanistic and safety foundation for the IV version. This strategic pivot reflects a nuanced understanding of regulatory pathways and unmet clinical needs, positioning the company to potentially capture value faster in a niche but critical segment of cannabis toxicity treatment.
The company’s decision to pursue voluntary delisting from Nasdaq and deregistration with the SEC, while seemingly defensive, could unlock substantial operational and financial efficiencies that directly benefit long-term value creation. By eliminating the recurring costs of SEC reporting, Sarbanes-Oxley compliance, audit fees, legal expenses, and Nasdaq listing standards, Anebulo can redirect significant capital toward its core R&D mission—particularly the advancement of the IV selonabant program. With cash and cash equivalents of $9,041,570 as of December 31, 2025, and a net loss narrowing to $1,999,397 for Q2 FY26 (down from $2,463,030 in the prior year period), the company is demonstrating improving financial discipline. The delisting process, expected to be completed by late February 2026, will reduce non-essential expenditures, allowing management to focus exclusively on clinical development and regulatory strategy without the distraction of public company obligations. This shift could extend the company’s cash runway meaningfully, especially if combined with potential non-dilutive funding from grants or partnerships, which the company has already shown success in securing (e.g., grant income of $552,576 in Q2 FY26).
The recent oversubscribed self-tender offer, in which 4,907,881 shares were tendered against an offer for only 300,000 shares at $3.50 per share, reveals strong underlying shareholder support and confidence in the company’s long-term vision, despite its clinical-stage status and lack of near-term revenue. The tender was oversubscribed by more than 16x, indicating that a significant portion of the shareholder base believes the current market price undervalues the company’s potential, particularly given the premium offered relative to recent trading levels. This level of participation suggests that institutional and retail investors alike are aligned with management’s strategic direction—focusing on pediatric IV selonabant and preparing for a potential future relisting or strategic transaction after value inflection points are achieved. The tender also reduced the shareholder base, which was a stated goal to facilitate deregistration, thereby streamlining governance and reducing administrative complexity. Far from being a sign of distress, this action reflects a proactive effort to align the shareholder structure with the company’s transition to a leaner, more focused operational model post-delisting.

▼ Bear case

Anebulo Pharmaceuticals faces significant hurdles in translating its promising preclinical and early clinical data into a commercially viable product, particularly given the absence of any late-stage clinical trials or regulatory engagements for selonabant despite completing Phase 2 studies in healthy adults over a year ago. The company has not initiated Phase 3 trials for either the oral or IV formulation, and its current focus on a Phase 1 SAD study for IV selonabant (initiated September 2025) places it years away from potential approval, especially for a pediatric indication requiring extensive safety and dosing data. The reliance on an observational study in emergency departments to gather real-world data on cannabis toxicity, while scientifically useful, does not substitute for controlled efficacy trials and may delay pivotal development timelines. Furthermore, the competitive antagonist mechanism of selonabant at the CB1 receptor, while biologically plausible, has not been validated in a pivotal trial setting, and there is no guarantee that reversing THC-induced CNS effects will translate into clinically meaningful outcomes such as reduced hospitalization or improved neurological recovery in real-world poisonings.
The company’s financial trajectory raises concerns about its ability to sustain operations through the lengthy and capital-intensive drug development process, particularly after delisting removes access to public equity markets as a future funding source. With total liabilities increasing to $1,485,646 as of December 31, 2025 (from $487,688 six months prior), driven likely by accrued expenses and obligations, the balance sheet shows worsening short-term financial pressure despite a declining net loss. Cash and cash equivalents fell to $9,041,570 from $11,627,849 over the same period, reflecting a quarterly burn rate of approximately $2.6 million in operating expenses, which at current levels would deplete reserves in under 15 months without additional financing. The delisting, while reducing compliance costs, will severely limit the company’s ability to raise capital through public offerings or attract institutional investors who mandate exchange-listed securities, forcing reliance on private placements, debt, or partnerships—each of which may come on unfavorable terms or dilute existing shareholders significantly.
The strategic pivot to pediatric IV selonabant, while potentially advantageous for approval speed, introduces substantial scientific and regulatory uncertainty that management may be underestimating. Developing an intravenous formulation for use in acutely intoxicated pediatric patients presents unique challenges, including dosing precision in emergency settings, formulation stability, and the need for extensive safety data in a vulnerable population—requirements that are far more rigorous than those for adult outpatient use. The company has not disclosed any preclinical toxicology or formulation stability data specific to the IV version, nor has it outlined a clear regulatory pathway with the FDA for a pediatric indication, which typically requires robust evidence of benefit-risk balance. Moreover, the assumption that an IV antidote will achieve faster approval than an oral product for adults overlooks the fact that pediatric indications often demand longer, more complex trials due to ethical considerations and difficulty in enrollment, potentially negating any perceived timeline advantage. Without clear milestones, IND-enabling data, or scheduled end-of-phase meetings with regulators, the IV strategy remains speculative and high-risk.

Anebulo Pharmaceuticals faces significant hurdles in translating its promising preclinical and early clinical data into a commercially viable product, particularly given the absence of any late-stage clinical trials or regulatory engagements for selonabant despite completing Phase 2 studies in healthy adults over a year ago. The company has not initiated Phase 3 trials for either the oral or IV formulation, and its current focus on a Phase 1 SAD study for IV selonabant (initiated September 2025) places it years away from potential approval, especially for a pediatric indication requiring extensive safety and dosing data. The reliance on an observational study in emergency departments to gather real-world data on cannabis toxicity, while scientifically useful, does not substitute for controlled efficacy trials and may delay pivotal development timelines. Furthermore, the competitive antagonist mechanism of selonabant at the CB1 receptor, while biologically plausible, has not been validated in a pivotal trial setting, and there is no guarantee that reversing THC-induced CNS effects will translate into clinically meaningful outcomes such as reduced hospitalization or improved neurological recovery in real-world poisonings.
The company’s financial trajectory raises concerns about its ability to sustain operations through the lengthy and capital-intensive drug development process, particularly after delisting removes access to public equity markets as a future funding source. With total liabilities increasing to $1,485,646 as of December 31, 2025 (from $487,688 six months prior), driven likely by accrued expenses and obligations, the balance sheet shows worsening short-term financial pressure despite a declining net loss. Cash and cash equivalents fell to $9,041,570 from $11,627,849 over the same period, reflecting a quarterly burn rate of approximately $2.6 million in operating expenses, which at current levels would deplete reserves in under 15 months without additional financing. The delisting, while reducing compliance costs, will severely limit the company’s ability to raise capital through public offerings or attract institutional investors who mandate exchange-listed securities, forcing reliance on private placements, debt, or partnerships—each of which may come on unfavorable terms or dilute existing shareholders significantly.
The strategic pivot to pediatric IV selonabant, while potentially advantageous for approval speed, introduces substantial scientific and regulatory uncertainty that management may be underestimating. Developing an intravenous formulation for use in acutely intoxicated pediatric patients presents unique challenges, including dosing precision in emergency settings, formulation stability, and the need for extensive safety data in a vulnerable population—requirements that are far more rigorous than those for adult outpatient use. The company has not disclosed any preclinical toxicology or formulation stability data specific to the IV version, nor has it outlined a clear regulatory pathway with the FDA for a pediatric indication, which typically requires robust evidence of benefit-risk balance. Moreover, the assumption that an IV antidote will achieve faster approval than an oral product for adults overlooks the fact that pediatric indications often demand longer, more complex trials due to ethical considerations and difficulty in enrollment, potentially negating any perceived timeline advantage. Without clear milestones, IND-enabling data, or scheduled end-of-phase meetings with regulators, the IV strategy remains speculative and high-risk.

Peer group

Peer Comparison

Companies in the Pharmaceuticals

S.No.	Ticker	Company	match	Market Cap	P/E	P/S	Total Debt (Qtr)
1	JNJ	Johnson & Johnson	primary	643.26 Bn	30.58	6.57	60.73 Bn
2	ABBV	AbbVie Inc.	primary	443.31 Bn	70.19	6.89	70.82 Bn
3	MRK	Merck & Co., Inc.	primary	364.74 Bn	115.10	5.48	53.91 Bn
4	NVS	Novartis Ag	primary	266.46 Bn	9.25	3.88	9.59 Bn
5	PFE	Pfizer Inc	primary	158.57 Bn	36.30	2.49	63.19 Bn
6	SNY	Sanofi	primary	52.33 Bn	11.23	0.98	25.19 Bn
7	RVMD	Revolution Medicines, Inc.	primary	43.79 Bn	-24.76	-	-
8	INCY	Incyte Corp	primary	25.23 Bn	15.65	4.34	0.04 Bn

Anebulo Pharmaceuticals ANEB

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password